Marking Dry Eye Awareness Month in July, EssilorLuxottica has announced a significant milestone for Espansione Group, a recent addition to the Group. The Company’s innovative eye-light solution, a leading light-based therapeutic platform, has been officially acknowledged in the prestigious TFOS (Tear Film and Ocular Surface Society) DEWS III Report.  

Published in the American Journal of Ophthalmology, this landmark inclusion recognizes Low-level Light Therapy (LLLT) photobiomodulation (PBM) as a management platform for tear film instability, dry eye disease (DED), and a broader spectrum of ocular surface conditions. 

The TFOS DEWS III¹ report, widely regarded as the most comprehensive global consensus on dry eye disease and tear film health, provides an evidence-based framework for eyecare professionals worldwide. Its updated guidance, an advancement from the 2017 TFOS DEWS II report, highlights the growing clinical acceptance of LLLT (PBM) and its synergy with Intense Pulsed Light (IPL) as effective tools for enhancing tear film stability and addressing the complex, multifactorial nature of DED. 

This acknowledgment is a significant milestone for Espansione Group, a pioneer in the MedTech industry and developer of light-based therapeutic technologies for ophthalmology and dermatology, which became part of the Company in February 2025.The eye-light device's debut in the DEWS III report underscores the increasing momentum and recognition for their proprietary technologies. 

The DEWS III report cites multiple peer-reviewed, randomized, and controlled trials demonstrating the efficacy of Espansione Group's Light Modulation LLLT (PBM ²) treatment, delivered via the eye-lightplatform, alongside IPL. These studies indicate significant improvements in tear-film stability, meibomian ³ gland function, and patient-reported symptoms. 

Beyond dry eye disease, the report also highlights the potential of Blue LLLT to impact bacterial-load related conditions, offering new avenues for managing blepharitis ⁴ through its antimicrobial properties. 

As EssilorLuxottica continues to innovate and expand its offerings, it remains committed to providing ECPs with evidence-based, non-pharmaceutical options that can be seamlessly integrated into comprehensive dry-eye and ocular surface management pathways, helping millions of patients achieve comfort and visual performance. 

 
_{1 The TFOS DEWS (Tear Film & Ocular Surface Society - Dry Eye Workshop) is an international working group which brings together experts in ophthalmology, optometry, cell biology, pharmacy, and others to produce scientific consensus reports on dry eye disease. 
2 PBM (photobiomodulation) is a therapeutic technique that uses low-level light to stimulate beneficial biological processes in cells and tissues. LLLT (Low-Level Laser Therapy) is a form of photobiomodulation using low-power lasers. 
3 Meibomian glands are specialized sebaceous glands located in the eyelids, within the free margin of each upper and lower eyelid. 
4 Blepharitis is a chronic inflammation of the eyelid margins, often bilateral, and may affect the lash area, the meibomian glands, or both.}